PR Newswire
prCenter
CAPR Class Action Alert: Capricor Therapeutics Clinical Data Issues and Subsequent 64% Stock Drop Lead to Investor Securities Fraud Class Action to Recover Lossestranslating…
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Leading securities…
Keywords#Securities#Action#Class#Class Action#Securities Fraud